Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.
Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tenn.
J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1533-1540.e8. doi: 10.1016/j.jaip.2018.12.003. Epub 2018 Dec 14.
The most common immediate hypersensitivity to macrogols is associated with polyethylene glycol (PEG) 3350; however, the epidemiology, mechanisms, and cross-reactivity are poorly understood. Thousands of medications contain either PEGs or structurally similar polysorbates.
Our objective was to better understand the mechanism, cross-reactivity, and scope of PEG hypersensitivity.
Two cases with a past history of immediate hypersensitivity to PEG-containing medications were used to study potential mechanisms and cross-reactivity of immediate reactions to PEG 3350. Skin testing and oral challenges with PEG and polysorbate-containing agents were employed to determine clinical reactivity and cross-reactivity between the 2 allergens. Enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay were used to detect anti-PEG specific IgG and IgE, respectively, using PEGylated protein or PEG alone as antigens in 2 cases and 6 PEG 3350 tolerant controls. We searched US Food and Drug Administration (FDA) adverse event reports for immediate reactions to PEG 3350 to determine the potential scope of this problem in the United States.
Skin and provocation testing demonstrated symptomatic reactivity in both cases to PEG 3350 and polysorbate 80. Plasma samples were positive for anti-PEG specific IgE and IgG antibodies only in cases and binding increased directly proportional to the molecular weight of PEG tested. FDA adverse event reports revealed 53 additional cases of possible PEG 3350 anaphylaxis.
Immediate hypersensitivity to PEG 3350 with cross-reactive polysorbate 80 hypersensitivity may be underrecognized in clinical practice and can be detected with clinical skin testing. Our studies raise the possibility of an IgE-mediated type I hypersensitivity mechanism in some cases.
最常见的对聚乙二醇(PEG)的即刻超敏反应与聚乙二醇 3350 有关;然而,其流行病学、机制和交叉反应性仍知之甚少。成千上万的药物中含有 PEG 或结构相似的聚山梨酯。
我们的目的是更好地了解 PEG 过敏的机制、交叉反应性和范围。
使用两例对含 PEG 药物有即刻过敏史的病例,研究对 PEG 3350 的即刻反应的潜在机制和交叉反应性。采用皮肤试验和含 PEG 和聚山梨酯的药物口服激发试验,以确定两种变应原之间的临床反应性和交叉反应性。采用酶联免疫吸附试验和电化学发光免疫分析,分别使用 PEG 化蛋白或 PEG 作为抗原,在 2 例和 6 例 PEG 3350 耐受对照中检测抗-PEG 特异性 IgG 和 IgE。我们在美国食品和药物管理局(FDA)不良事件报告中搜索了对 PEG 3350 的即刻反应,以确定该问题在美国的潜在范围。
皮肤和激发试验显示,两例患者均对 PEG 3350 和聚山梨酯 80 有症状性反应。仅在病例中,血浆样本中检测到抗-PEG 特异性 IgE 和 IgG 抗体阳性,且结合量与所测试的 PEG 分子量成正比增加。FDA 不良事件报告显示,可能有 53 例 PEG 3350 过敏反应的病例。
对 PEG 3350 的即刻过敏反应伴有交叉反应性聚山梨酯 80 过敏反应,在临床实践中可能认识不足,可通过临床皮肤试验检测到。我们的研究提出了在某些情况下可能存在 IgE 介导的 I 型超敏反应机制的可能性。